Buruli ulcer

被引：123

作者：

Portaels, Francoise ^{[1
]}

Silva, Manuel T. ^{[2
]}

Meyers, Wayne M. ^{[3
]}

机构：

[1] Inst Trop Med, Mycobacteriol Unit, B-2000 Antwerp, Belgium

[2] Inst Biol Mol & Celular, P-4150180 Oporto, Portugal

[3] Armed Forces Inst Pathol, Dept Environm & Infect Dis Sci, Washington, DC 20306 USA

来源：

CLINICS IN DERMATOLOGY | 2009年 / 27卷 / 03期

关键词：

MYCOBACTERIAL SKIN ULCERS; HOST IMMUNE-RESPONSE; PROTECTIVE EFFICACY; RISK-FACTORS; DNA VACCINE; WHOLE-BLOOD; BOVIS BCG; IN-VITRO; DISEASE; INFECTION;

D O I：

10.1016/j.clindermatol.2008.09.021

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Buruli ulcer is an indolent necrotizing disease of the skin, subcutaneous tissue, and bone that is caused by Mycobacterium ulcerans. Buruli ulcer is presently the third most common mycobacterial disease of humans, after tuberculosis and leprosy, and the least understood of the three. The disease remained largely ignored by many national public health programs, but more recently, it has been recognized as an emerging health problem, primarily due to its frequent disabling and stigmatizing complications. The contribution discusses various aspects of Buruli ulcer, including its geographic distribution, incidence, and prevalence; mode of transmission, pathogenesis, and immunity; clinical manifestations; laboratory diagnosis; differential clinical diagnosis; and treatment. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：291 / 305

页数：15

共 96 条

[1] Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M-ulcerans in vitro and in vivo [J].

Adusumilli, S ;

Mve-Obiang, A ;

Sparer, T ;

Meyers, W ;

Hayman, J ;

Small, PLC .

CELLULAR MICROBIOLOGY, 2005, 7 (09) :1295-1304

[2] Temporal pore formation-mediated egress from macrophages and alveolar epithelial cells by Legionella pneumophila [J].

Alli, OAT ;

Gao, LY ;

Pedersen, LL ;

Zink, S ;

Radulic, M ;

Doric, M ;

Abu Kwaik, Y .

INFECTION AND IMMUNITY, 2000, 68 (11) :6431-6440

[3]

Asiedu K., 2000, MYCOBACTERIUM ULCERA

[4]

Aujoulat I, 1996, DEV SANTE, V125, P22

[5]

BUNTINE J, 2001, BURULI ULCER MANAGEM

[6] Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)v [J].

Chauty, Annick ;

Ardant, Marie-Francoise ;

Adeye, Ambroise ;

Euverte, Helene ;

Guedenon, Augustin ;

Johnson, Christian ;

Aubry, Jacques ;

Nuermberger, Eric ;

Grosset, Jacques .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4029-4035

[7]

CLANCEY JK, 1961, LANCET, V2, P951

[8]

CONNOR DH, 1976, PATHOLOGY TROPICAL E, V1, P26

[9] Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans:: the contribution of endogenous mycolactone toxin [J].

Coutanceau, E ;

Marsollier, L ;

Brosch, R ;

Perret, E ;

Goossens, P ;

Tanguy, M ;

Cole, ST ;

Small, PLC ;

Demangel, C .

CELLULAR MICROBIOLOGY, 2005, 7 (08) :1187-1196

[10] Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer [J].

Coutanceau, Emmanuelle ;

Legras, Pierre ;

Marsollier, Laurent ;

Reysset, Gilles ;

Cole, Stewart T. ;

Demangel, Caroline .

MICROBES AND INFECTION, 2006, 8 (08) :2075-2081

← 1 2 3 4 5 6 7 8 9 10 →